Pfizer sets out on $17 billion acquisition trail
pharmafile | July 21, 2006 | News story | Sales and Marketing | Pfizer
Pfizer, the world's biggest pharmaceutical company, has earmarked $17 billion to spend on new products and technologies over the next 30 months.
The company recently sold its consumer products business to Johnson & Johnson for $16.6 billion and is focusing on its core human health business after a challenging few years.
The pharma company is being hit hard by patent expiries and in the four years to 2008, it will have lost about a third of its Human Health division's revenue.
Chief executive Hank McKinnell said: "Many companies could not survive such a profound loss of revenue. The strong performance of our in-line product portfolio and the large potential of our new-product pipeline demonstrate our ability to generate substantial new revenues to create the next-generation Pfizer."
The company has seen strong double-digit performance from several existing products in the second-quarter of this year, including its cholesterol-lowering star Lipitor, arthritic pain treatment Celebrex and the anti-psychotic Geodon.
Already the biggest-selling drug in the world, Lipitor's sales increased by 9% in the quarter to $3.1 billion and Pfizer is aiming for a full-year sales for the product of $13 billion.
President of Pfizer Human Health Karen Katen admitted this target was a 'stretch goal' in light of the introduction of cheaper, generic versions of a rival statin, Merck's Zocor (simvastatin).
"While our Lipitor sales target remains ambitious, we believe we can achieve it," she said. "We have a strong clinical platform that clearly differentiates Lipitor from all other agents."
Sales of Lipitor made a significant contribution to Pfizer's second-quarter revenue, which grew ahead of expectations, increasing by 3% between 2005 and 2006 to $11.7 billion. The company is aiming for full-year sales growth in 2007 and 2008 in the high single digits.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
